Gene therapy, considered to be the most efficient and sometimes only treatment option for many severe and life-threatening diseases, is shifting to more common indications with higher numbers of patients including Parkinson’s and Alzheimer’s disease. This is where the new ELEVECTA® AAV producer cell lines come into play. ELEVECTA® is a revolutionary technology that enables viral vector manufacturing in an industry-standard, scalable suspension format.
NodThera bags US$55m in Series B round
Latest NewsNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
Bacterial colonisation differs by tumour type
Latest NewsAn analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
ELEVECTA® Unlocking The Full Potential of Gene Therapy
Sponsored PublicationsGene therapy, considered to be the most efficient and sometimes only treatment option for many severe and life-threatening diseases, is shifting to more common indications with higher numbers of patients including Parkinson’s and Alzheimer’s disease. This is where the new ELEVECTA® AAV producer cell lines come into play. ELEVECTA® is a revolutionary technology that enables viral vector manufacturing in an industry-standard, scalable suspension format.
New algorithm predicts rheumatoid arthritis
Latest NewsBased on genetic data, a new diagnostic algorithm can differentiate between five different rheumatic diseases.
Evox Therapeutics appoints Chief Medical Officer
AppointmentsOxford-based Evox Therapeutics appoints Sonya Montgomery in the newly formed position of Chief Medical Officer.
Novo Holdings invests into AI CRO ExScientia
Latest NewsPoxel SA raises €17.7m through capital increase
Latest NewsMetabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at €0.02 per share reserved to specified investors.
Study might prepare for rapid revision of EU GMO law
BackgroundThe European Commission has taken up the European Council’s demand for deregulation of new plant breeding techniques (NBT). A new study is being conducted to form the basis for a campaign from the Commission to inform the public about the benefits of targeted mutation technologies and to break the resistance to genetically engineered crops.
British scientists start Phase II on COVID-19 vaccine
Latest NewsResearchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.
Non-Executive Director for Redx Pharma
AppointmentsFrom the beginning of July, Sarah Gordon Wild will be an Independent non-Executive Director at Redx Pharma in Alderley Park, UK.